Cartalax
A synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, studied for cartilage-protective and geroprotective effects in preclinical models.
Also referenced as: AED, Ala-Glu-Asp
Also appears in: Longevity
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Cartalax crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Tissue repair. Also surfaces under Longevity for browsing and discovery.
AED, Ala-Glu-Asp
No FDA label signal · 289 trials · 8146 PubMed results
Cartalax has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Cartalax has 11 name-matched clinical trials (highest phase: Phase 3) and 8146 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.
- 2026-08-25 Preclinical → Promising Band Preclinical → Promising; +8 trials; +1 PubMed
- 2026-08-22 Promising → Preclinical Band Promising → Preclinical; -2 trials; +1 PubMed
- 2026-08-18 Preclinical → Promising Band Preclinical → Promising; +12 trials
- 2026-08-15 Promising → Preclinical Band Promising → Preclinical; -12 trials; +2 PubMed
- 2026-08-14 Preclinical → Promising Band Preclinical → Promising; +12 trials; +2 PubMed
- 2026-08-13 Promising → Preclinical Band Promising → Preclinical; -9 trials; +1 PubMed
- 2026-08-05 Preclinical → Promising Band Preclinical → Promising; +6 trials; +1 PubMed
- 2026-08-01 Promising → Preclinical Band Promising → Preclinical; -6 trials; +1 PubMed
- 2026-07-09 Promising First graded
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-17 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Cartalax?
Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (AED), developed as part of Vladimir Khavinson’s bioregulator peptide program at the Saint Petersburg Institute of Bioregulation and Gerontology. It is classified as a cartilage-tissue bioregulator and is often discussed alongside other Khavinson peptides like Epitalon, Pinealon, and Thymalin.
How it works
The proposed mechanism follows the Khavinson bioregulation model:
- Peptide-DNA interaction — short peptides are theorized to penetrate cell nuclei and modulate gene expression in a tissue-specific manner (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Cartilage matrix support — Cartalax is proposed to regulate genes involved in proteoglycan and collagen synthesis in chondrocytes, though the specific gene targets have not been identified in Western literature
- Geroprotective effects — in rodent aging studies, combinations of short bioregulatory peptides (including AED-containing preparations) have been associated with improved tissue function in aged animals (Khavinson, Gerontology, 2005)
Research status
- Khavinson (2005) reviewed 35 years of bioregulator peptide research including cartilage-targeted peptides (Gerontology, 51(2):70–75)
- Khavinson & Malinin (2005) described the theoretical basis for tissue-specific short peptide bioregulation (Neuroendocrinology Letters, 26(3):233–238)
- Anisimov et al. (2003) showed life extension in rodents treated with bioregulator peptide preparations (Annals of the New York Academy of Sciences, 992:141–147)
The evidence base is primarily Russian-language publications from the Khavinson group. No independent Western replication studies or human clinical trials have been published.
Key considerations
- Part of a family of Khavinson bioregulators commonly sold together (Cartalax + Pinealon + Epitalon combinations)
- Research originates from a single group with limited independent replication
- Often combined with BPC-157 and TB-500 by vendors in recovery-oriented blends
- Available as lyophilized powder or capsules from research vendors